Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies
PLoS neglected tropical diseases2016Vol. 10(2), pp. e0004362–e0004362
Citations Over TimeTop 15% of 2016 papers
C. Burri, Patrick Yeramian, James L. Allen, Ada Merolle, Kazadi Kyanza Serge, Alain Mpanya, Pascal Lutumba, Victor Kande Betu Ku Mesu, Constantin Miaka Mia Bilenge, Jean-Pierre Fina Lubaki, Alfred Mpoo Mpoto, Mark S. Thompson, Blaise Fungula Munungu, Francisco Manuel, Théophilo Josenando, Sonja Bernhard, Carol A. Olson, Johannes Blum, Richard R. Tidwell, Gabriele Pohlig
Abstract
Pafuramidine for the treatment of first stage HAT was comparable in efficacy to pentamidine after 10 days of dosing. The cure rates 3 months post-treatment were 79% in the 5-day pafuramidine, 100% in the 7-day pentamidine, and 93% in the 10-day pafuramidine groups. In Phase 2b, the percentage of patients with at least 1 treatment-emergent adverse event was notably higher after pentamidine treatment (93%) than pafuramidine treatment for 5 days (25%) and 10 days (57%). These results support continuation of the development program for pafuramidine into Phase 3.
Related Papers
- → Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story(2013)251 cited
- → How to Shorten Patient Follow‐Up after Treatment forTrypanosoma brucei gambienseSleeping Sickness(2010)68 cited
- → Human African trypanosomiasis(2020)21 cited
- → Assessing three day pentamidine for early stage human African trypanosomiasis (Angola)(2012)
- → Human African Trypanosomiasis: The Smoldering Scourge of Africa(2023)